Second-Line Chemotherapy and Beyond for Non–Small Cell Lung Cancer

Greg Durm, Nasser Hanna

Research output: Contribution to journalReview article

5 Scopus citations

Abstract

The landscape for the second- and third-line treatment of advanced non–small cell lung cancer has changed dramatically over the last two decades. Immunotherapeutic agents have become a preferred choice following progression on platinum-based first-line chemotherapy. However, there remains a role for cytotoxic chemotherapy and pemetrexed and docetaxel (with or without ramucirumab) are approved for single-agent use in the second-line setting. With the discovery of new genetic alterations and the development of novel targeted drugs, the treatment of advanced non–small cell lung cancer following progression on first-line therapy continues to become more complicated as new treatment algorithms evolve.

Original languageEnglish (US)
Pages (from-to)71-81
Number of pages11
JournalHematology/Oncology Clinics of North America
Volume31
Issue number1
DOIs
StatePublished - Feb 1 2017

Keywords

  • Chemotherapy
  • Docetaxel
  • Erlotinib
  • Non–small cell lung cancer
  • Pemetrexed
  • Second-line treatment

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Second-Line Chemotherapy and Beyond for Non–Small Cell Lung Cancer'. Together they form a unique fingerprint.

  • Cite this